The latest options and future agents for treating male hypogonadism

Expert Opinion on Pharmacotherapy

Volumn 8, Issue 17, 2007, Pages 2991-3008

  Edelstein, Daniel ^a   Sivanandy, Mala ^b   Shahani, Sadeka ^b   Basaria, Shehzad ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Department of Women's Health ^*  (United States)

Author keywords

Androgen replacement therapy; Hypgonadism; SARMS; Testosterone

Indexed keywords

1,2,3,4 TETRAHYDROQUINOLINE DERIVATIVE; ANASTROZOLE; ANDARINE; ANDRIDIOL TESTOCAPS; ANDRIN; ANDROGEN RECEPTOR; ANDROSTANOLONE; AROMATASE INHIBITOR; BMS 564929; CLOMIFENE CITRATE; ENCLOMIFENE CITRATE; HYDANTOIN DERIVATIVE; LGD 2226; METHYLESTRENOLONE; OSTARINE; PLACEBO; PROPIONAMIDE DERIVATIVE; QUINOLINE DERIVATIVE; RECOMBINANT CHORIONIC GONADOTROPIN; S 40503; SEX HORMONE BINDING GLOBULIN; TESTOSTERONE; TESTOSTERONE DERIVATIVE; TESTOSTERONE ENANTATE; TESTOSTERONE UNDECANOATE; TRESTOLONE; TRIAMCINOLONE ACETONIDE; UNCLASSIFIED DRUG;

ANDROGEN DEFICIENCY; ANXIETY; APPLICATION SITE ERYTHEMA; APPLICATION SITE IRRITATION; BITTER TASTE; BREAST TENDERNESS; CLINICAL TRIAL; DEPRESSION; DOSAGE SCHEDULE COMPARISON; DRUG CLEARANCE; DRUG COST; DRUG DOSAGE FORM COMPARISON; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG ERUPTION; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; DRUG WITHDRAWAL; ERECTILE DYSFUNCTION; GASTROINTESTINAL SYMPTOM; GINGIVITIS; GYNECOMASTIA; HORMONE SUBSTITUTION; HOT FLUSH; HUMAN; HYPERGONADOTROPIC HYPOGONADISM; HYPERTENSION; HYPOGONADISM; INJECTION SITE DISCOMFORT; INJECTION SITE PAIN; INSOMNIA; LIBIDO; LIVER FUNCTION TEST; LOADING DRUG DOSE; MALE; MASTALGIA; MAXIMUM PLASMA CONCENTRATION; MENTAL INSTABILITY; MOUTH EDEMA; MOUTH INFLAMMATION; NAUSEA; NERVOUSNESS; NONHUMAN; ORAL BLISTER; PATIENT COMPLIANCE; PENIS ERECTION; PHARMACOGENETICS; POLYCYTHEMIA; REVIEW; SEXUAL FUNCTION; SIDE EFFECT; SKIN ALLERGY; SKIN INDURATION; SKIN IRRITATION; SKIN MANIFESTATION; STOMATITIS; TESTOSTERONE BLOOD LEVEL; TESTOSTERONE METABOLISM; TESTOSTERONE SYNTHESIS; TOOTH PAIN; UNSPECIFIED SIDE EFFECT; XEROSTOMIA;

ANDROGENS; CHEMISTRY, PHARMACEUTICAL; DRUG ADMINISTRATION ROUTES; DRUG DESIGN; DRUGS, INVESTIGATIONAL; HORMONE REPLACEMENT THERAPY; HUMANS; HYPOGONADISM; MALE; PATIENT SELECTION; TESTOSTERONE; TREATMENT OUTCOME;

EID: 37349108187     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.8.17.2991     Document Type: Review

References (103)

1. BAGATELL CJ, BREMNER WJ: Androgens in men - uses and abuses. N. Engl. J. Med. (1996) 334(11):707-714.
2. PLYMATE SR: Hypogonadism in men: an overview. In: Androgens in Health and Disease. Bagatell CJ, Bremner W (Eds), Humana Press, New Jersey, US (2003):45-76.
3. NIESCHLAG E, SWERDLOFF R, BEHRE HM et al.: Investigation, treatment and monitoring of late-onset hypogonadism in males: ISA, ISSAM, and EAU recommendations. Int. J. Androl. (2005) 28(3):125-127.
4. HARMAN SM, METIER EJ, TOBIN JD et al.: Longitudinal effects of aging on serum total and free testosterone levels in healthy men. Baltimore longitudinal study of aging. J. Clin. Endocrinol. Metab. (2001) 86(2):724-731.
5. MORLEY JE, KAISER FE, PERRY HM III et al.: Longitudinal changes in testosterone, luteinizing hormone, and follicle-stimulating hormone in healthy older men. Metabolism (1997) 46(4):410-413.
6. SNYDER PJ: Effects of age on testicular function and consequences of testosterone treatment. J. Clin. Endocrinol. Metab. (2001) 86(6):2369-2372.
7. VERMEULEN A: Androgen replacement therapy in the aging male - a critical evaluation. J. Clin. Endocrinol. Metab. (2001) 86(6):2380-2390.
8. KAUFMAN JM, VERMEULEN A: Declining gonadal function in elderly men. Baillieres Clin. Endocrinol. Metab. (1997) 11(2):289-309.
9. PLYMATE SR, TENOVER JS, BREMNER WJ: Circadian variation in testosterone, sex hormone-binding globulin, and calculated non-sex hormone-binding globulin bound testosterone in healthy young and elderly men. J. Androl. (1989) 10(5):366-371.
10. BREMNER WJ, VITIELLO MV, PRINZ PN: Loss of circadian rhythmicity in blood testosterone levels with aging in normal men. J. Clin. Endocrinol. Metab. (1983) 56(6):1278-1281.
11. DUNN JF, NISULA BC, RODBARD D: Transport of steroid hormones: binding of 21 endogenous steroids to both testosterone-binding globulin and corticosteroid-binding globulin in human plasma. J. Clin. Endocrinol. Metab. (1981) 53(1):58-68.
12. VERMEULEN A, VERDONCK L, KAUFMAN JM: A critical evaluation of simple methods for the estimation of free testosterone in serum. J. Clin. Endocrinol. Metab. (1999) 84(10):3666-3672.
13. WINTERS SJ, KELLEY DE, GOODPASTER B: The analog free testosterone assay: are the results in men clinically useful? Clin. Chem. (1998) 44(10):2178-2182.
14. DIVER MJ, IMTIAZ KE, AHMAD AM et al.: Diurnal rhythms of serum total, free and bioavailable testosterone and of SHBG in middle-aged men compared with those in young men. Clin. Endocrinol. (Oxf.) (2003) 58(6):710-717.
15. WINTERS SJ, CLARK BJ: Testosterone synthesis, transport, and metabolism. In: Androgens in Health and Disease. Bagatell CJ, Bremner WJ (Eds), Humana Press, New Jersey, US (2003):3-22.
16. LARSEN PR, KRONENBERG HM, SHLOMO M, POLONSKY KS, WILSON JD: Williams Textbook of Endocrinology (10th Edition), Saunders, Philadelphia, PA (2003):1927.
17. GOOREN L, BUNCK JMC: Androgen replacement therapy: present and future. Drugs (2004) 64(17):1861-1891.
18. SCHUBERT M, MINNEMANN T, HUBLER D et al.: Intramuscular testosterone undecanoate: pharmacokinetic aspects of a novel testosterone formulation during long-term treatment of men with hypogonadism. J. Clin. Endocrinol. Metab. (2004) 89(11):5429-5434.
19. HORST HJ, HOLTJE WJ, DENNIS M et al.: Lymphatic absorption and metabolism of orally administered testosterone undecanoate In man. Klin. Wochenschr. (1976) 54(18):875-879.
20. MARIN P, HOLMANG S, JONSSON L et al.: The effects of testosterone treatment on body composition and metabolism in middle-aged obese men. Int. J. Obes. Relat. Metab. Disord. (1992) 16(12):991-997.
21. SCHUBERT M, BULLMANN C, MINNEMANN T et al.: Osteoporosis in male hypogonadism: responses to androgen substitution differ among men with primary and secondary hypogonadism. Horm. Res. (2003) 60(1):21-28.
22. GOOREN LJ: A ten-year safety study of the oral androgen testosterone undecanoate. J. Androl. (1994) 15(3):212-215.
23. SKAKKEBAEK NE, BANCROFT J, DAVIDSON DW, WARNER P: Androgen replacement with oral testosterone undecanoate in hypogonadal men: a double blind controlled study. Clin. Endocrinol. (Oxf.) (1981) 14(1):49-61.
24. MORALES A, JOHNSTON B, HEATON JP, LUNDIE M: Testosterone supplementation for hypogonadal impotence: assessment of biochemical measures and therapeutic outcomes. J. Urol. (1997) 157(3):849-854.
25. VON ECKARDSTEIN S, NIESCHLAG E: Treatment of male hypogonadism with testosterone undecanoate injected at extended intervals of 12 weeks: a Phase II study. J. Androl. (2002) 23(3):419-425.
26. BEHRE HM, ABSHAGEN K, OETTEL M et al.: Intramuscular injection of testosterone undecanoate for the treatment of male hypogonadism: Phase I studies. Eur. J. Endocrinol. (1999) 140(5):414-419.
27. ZHANG GY, GU YQ, WANG XH et al.: A pharmacokinetic study of injectable testosterone undecanoate in hypogonadal men. J. Androl. (1998) 19(6):761-768.
28. DOBS AS, MEIKLE AW, ARVER S et al.: Pharmacokinetics, efficacy, and safety of a permeation-enhanced testosterone transdermal system in comparison with bi-weekly injections of testosterone enanthate for the treatment of hypogonadal men. J. Clin. Endocrinol. Metab. (1999) 84(10):3469-3478.
29. ANDERSON RA, BANCROFT J, WU FC: The effects of exogenous testosterone on sexuality and mood of normal men. J. Clin. Endocrinol. Metab. (1992) 75(6):1503-1507.
30. HARLE L, BASARIA S, DOBS AS: Nebido: a long-acting injectable testosterone for the treatment of male hypogonadism. Expert Opin. Pharmacother. (2005) 6(10):1751-1759.
31. NIESCHLAG E, BUCHTER D, VON ECKARDSTEIN S et al.: Repeated intramuscular injections of testosterone undecanoate for substitution therapy in hypogonadal men. Clin. Endocrinol. (Oxf.) (1999) 51(6):757-763.
32. ZITZMANN M: Long-term experience of more than 8 years with a novel formulation of testosterone undecanoate (Nebido) in substitution therapy of hypogonadal men "aging male". The 5th World Conference on the Aging Male. Salzburg, Austria (9-12 February 2006).
33. KIM S, SNIPES W, HODGEN GD, ANDERSON F: Pharmacokinetics of a single dose of buccal testosterone. Contraception (1995) 52(5):313-316.
34. KORBONITS M, SLAWIK M, CULLEN D et al.: A comparison of a novel testosterone bioadhesive buccal system, striant, with a testosterone adhesive patch in hypogonadal males. J. Clin. Endocrinol. Metab. (2004) 89(5):2039-2043.
35. DOBS AS, MATSUMOTO AM, WANG C, KIPNES MS: Short-term pharmacokinetic comparison of a novel testosterone buccal system and a testosterone gel in testosterone deficient men. Curr. Med. Res. Opin. (2004) 20(5):729-738.
36. ARVER S, DOBS AS, MEIKLE AW et al.: Improvement of sexual function in testosterone deficient men treated for 1 year with a permeation enhanced testosterone transdermal system. J. Urol. (1996) 155(5):1604-1608.
37. ARVER S, DOBS AS, MEIKLEA W et al.: Long-term efficacy and safety of a permeation-enhanced testosterone transdermal system in hypogonadal men. Clin. Endocrinol. (Oxf.) (1997) 47(6):727-737.
38. MEIKLE AW, ARVER S, DOBS AS et al.: Pharmacokinetics and metabolism of a permeation-enhanced testosterone transdermal system in hypogonadal men: influence of application site - a clinical research center study. J. Clin. Endocrinol. Metab. (1996) 81(5):1832-1840.
39. JAIN P, RADEMAKER AW, MCVARY KT: Testosterone supplementation for erectile dysfunction: results of a meta-analysis. J. Urol. (2000) 164(2):371-375.
40. WILSON DE, KAIDBURY K, BOIKE SC, JORKASKY DK: Use of topical corticosteroid pretreatment to reduce the incidence and severity of skin reactions associated with testosterone transdermal therapy. Clin. Ther. (1998) 20(2):299-306.
41. WANG C, BERMAN N, LONGSTRETH JA et al.: Pharmacokinetics of transdermal testosterone gel in hypogonadal men: application of gel at one site versus four sites: a general clinical research center study. J. Clin. Endocrinol. Metab. (2000) 85(3):964-969.
42. SWERDLOFF RS, WANG C, CUNNINGHAM G et al.: Long-term pharmacokinetics of transdermal testosterone gel in hypogonadal men. J. Clin. Endocrinol. Metab. (2000) 85(12):4500-4510.
43. STEIDLE C, SCHWARTZ S, JACOBY K et al.: AA2500 testosterone gel normalizes androgen levels in aging males with improvements in body composition and sexual function. J. Clin. Endocrinol. Metab. (2003) 88(6):2673-2681.
44. WANG C, CUNNINGHAM G, DOBS A et al.: Long-term testosterone gel (AndroGel) treatment maintains beneficial effects on sexual function and mood, lean and fat mass, and bone mineral density in hypogonadal men. J. Clin. Endocrinol. Metab. (2004) 89(5):2085-2098.
45. WANG C, SWERDLOFF RS, IRANMANESH A et al.: Effects of transdermal testosterone gel on bone turnover markers and bone mineral density in hypogonadal men. Clin. Endocrinol. (Oxf.) (2001) 54(6):739-750.
46. POPE HG Jr, COHANE GH, KANAYAMA G et al.: Testosterone gel supplementation for men with refractory depression: a randomized, placebo-controlled trial. Am. J. Psychiatry (2003) 160(1):105-111.
47. ROLF C, KNIE U, LEMMNITZ G, NIESCHLAG E: Interpersonal testosterone transfer after topical application of a newly developed testosterone gel preparation. Clin. Endocrinol. (Oxf.) (2002) 56(5):637-641.
48. MARBURY T, HAMILL E, BACHAND R et al.: Evaluation of the pharmacokinetic profiles of the new testosterone topical gel formulation, Testim, compared to AndroGel. Biopharm. Drug Dispos. (2003) 24(3):115-120.
49. MCNICHOLAS TA, DEAN JD, MULDER H et al.: A novel testosterone gel formulation normalizes androgen levels in hypogonadal men, with improvements in body composition and sexual function. BJU Int. (2003) 91(1):69-74.
50. WANG C, SWERDLOFF RS, IRANMANESH A et al.: Transdermal testosterone gel improves sexual function, mood, muscle strength, and body composition parameters in hypogonadal men. J. Clin. Endocrinol. Metab. (2000) 85(8):2839-2853.
51. NEGRO-VILAR A: Selective androgen receptor modulators (SARMs): a novel approach to androgen therapy for the new millennium. J. Clin. Endocrinol. Metab. (1999) 84(10):3459-3462.
52. BHASIN S, BUCKWALTER JG: Testosterone supplementation in older men: a rational idea whose time has not yet come. J. Androl. (2001) 22(5):718-731.
53. GAO W, REISER PJ, COSS CC et al.: Selective androgen receptor modulator treatment improves muscle strength and body composition and prevents bone loss in orchidectomized rats. Endocrinology (2005) 146(11):4887-4897.
54. ROSEN J, NEGRO-VILAR A: Novel, non-steroidal, selective androgen receptor modulators (SARMs) with anabolic activity in bone and muscle and improved safety profile. J. Musculoskelet. Neuro. Interact. (2002) 2(3):222-224.
55. HAMMAN LG: Discovery and preclinical profile of a highly potent and muscle selective androgen receptor modulator (SARM). 227th National Meeting of the American Chemical Society Medicinal Chemistry Division (ACSMCC). Anaheim, CA (28 March - 1 April 2004).
56. HANADA K, FURUYA K, YAMAMOTO N et al.: Bone anabolic effects of S-40503, a novel nonsteroidal selective androgen receptor modulator (SARM), in rat models of osteoporosis. Biol. Pharm. Bull. (2003) 26(11):1563-1569.
57. MARHEFKA CA, GAO W, CHUNG K et al.: Design, synthesis, and biological characterization of metabolically stable selective androgen receptor modulators. J. Med. Chem. (2004) 47(4):993-998.
58. YIN D, GAO W, KEARBEY JD et al.: Pharmacodynamics of selective androgen receptor modulators. J. Pharmacol. Exp. Ther. (2003) 304(3):1334-1340.
59. YIN D, HE Y, PERERA MA et al.: Key structural features of nonsteroidal ligands for binding and activation of the androgen receptor. Mol. Pharmacol. (2003) 63(1):211-223.
60. EDWARDS JP, WEST SJ, POOLEY CL et al.: New nonsteroidal androgen receptor modulators based on 4-(trifluoromethyl)-2(1H)-pyrrolidino [3,2-g] quinolinone. Bioorg. Med. Chem. Lett. (1998) 8(7):745-750.
61. HWANG DJ, YANG J, XU H et al.: Asylisothiocyanato selective androgen receptor modulators (SARMs) for prostate cancer. Bioorg. Med. Chem. (2006).
62. CADILLA R, TURNBULL P: Selective androgen receptor modulators in drug discovery: medicinal chemistry and therapeutic potential. Curr. Top. Med. Chem. (2006) 6(3):245-270.
63. SEGAL S, NARAYANAN R, DALTON JT: Therapeutic potential of the SARMs: revisiting the androgen receptor for drug discovery. Expert Opin. Investig. Drugs (2006) 15(4):377-387.
64. CHEN J, KIM J, DALTON JT: Discovery and therapeutic promise of selective androgen receptor modulators. Mol. Interv. (2005) 5(3):173-188.
65. CUMMINGS DE, KUMAR N, BARDIN CW et al.: Prostate-sparing effects in primates of the potent androgen 7α-methyl-19-nortestosterone: a potential alternative to testosterone for androgen replacement and male contraception. J. Clin Endocrinol. Metab. (1998) 83(12):4212-4219.
66. ANDERSON RA, MARTIN CW, KUNG AW et al.: 7α-Methyl-19-nortestosterone maintains sexual behavior and mood in hypogonadal men. J. Clin. Endocrinol. Metab. (1999) 84(10):3556-3562.
67. SUVISAARI J, SUNDARAM K, NOE G et al.: Pharmacokinetics and pharmacodynamics of 7α-methyl-19-nortestosterone after intramuscular administration in healthy men. Hum. Reprod. (1997) 12(5):967-973.
68. ANDERSON RA, WALLACE AM, SATTAR N et al.: Evidence for tissue selectivity of the synthetic androgen 7α-methyl-19-nortestosterone in hypogonadal men. J. Clin. Endocrinol. Metab. (2003) 88(6):2784-2793.
69. SHAO TC, LI HL, KASPER S et al.: Comparison of the growth-promoting effects of testosterone and 7-α-methyl-19-nor-testosterone (MENT) on the prostate and levator ani muscle of LPB-tag transgenic mice. Prostate (2006) 66(4):369-376.
70. VENKEN K, BOONEN S, VAN HERCK E et al.: Bone and muscle protective potential of the prostate-sparing synthetic androgen 7α-methyl-19-nortestosterone: evidence from the aged orchidectomized male rat model. Bone (2005) 36(4):663-670.
71. CHOI SK, HAN SW, KIM DH, DE LIGNIERES B: Transdermal dihydrotestosterone therapy and its effects on patients with microphallus. J. Urol. (1993) 150(2 Part 2):657-660.
72. SWERDLOFF RS, WANG C: Dihydrotestosterone: a rationale for its use as a non-aromatizable androgen replacement therapeutic agent. Baillieres Clin. Endocrinol. Metab. (1998) 12(3):501-506.
73. WANG C, SWERDLOFF RS: Should the nonaromatizable androgen dihydrotestosterone be considered as an alternative to testosterone in the treatment of the andropause? J. Clin. Endocrinol. Metab. (2002) 87(4): 1462-1466.
74. SCHAISON G, COUZINET B: Percutaneous dihydrotestosterone (DHT) treatment. In: Testosterone: Action, Deficiency, Substitution. Nieschlag E, Behre HM, (Eds), Springer Verlag, Berlin (1998):423-436.
75. DE LIGNIERES B: Transdermal dihydrotestosterone treatment of 'andropause'. Ann. Med. (1993) 25(3):235-241.
76. LY LP, JIMENEZ M, ZHUANG TN et al.: A double-blind, placebo-controlled, randomized clinical trial of transdermal dihydrotestosterone gel on muscular strength, mobility, and quality of life in older men with partial androgen deficiency. J. Clin. Endocrinol. Metab. (2001) 86(9):4078-4088.
77. KUNELIUS P, LUKKARINEN O, HANNUKSELA ML et al.: The effects of transdermal dihydrotestosterone in the aging male: a prospective, randomized, double blind study. J. Clin. Endocrinol. Metab. (2002) 87(4):1467-1472.
78. LEDER BZ, ROHRER JL, RUBIN SD et al.: Effects of aromatase inhibition in elderly men with low or borderline-low serum testosterone levels. J. Clin. Endocrinol. Metab. (2004) 89(3):1174-1180.
79. TAXEL P, KENNEDY DG, FALL PM et al.: The effect of aromatase inhibition on sex steroids, gonadotropins, and markers of bone turnover in older men. J. Clin. Endocrinol. Metab. (2001) 86(6):2869-2874.
80. RAMAN JD, SCHLEGEL PN: Aromatase inhibitors for male infertility. J. Urol. (2002) 167(2 Part 1)):624-629.
81. CUNNINGHAM GR, CORDERO E, THORNBY JI: Testosterone replacement with transdermal therapeutic systems. Physiological serum testosterone and elevated dihydrotestosterone levels. JAMA (1989) 261(17):2525-2530.
82. GUAY AT, BANSAL S, HEATLEY GJ: Effect of raising endogenous testosterone levels in impotent men with secondary hypogonadism: double blind placebo-controlled trial with clomiphene citrate. J. Clin. Endocrinol. Metab. (1995) 80(12):3546-3552.
83. GUAY AT, JACOBSON J, PEREZ JB et al.: Clomiphene increases free testosterone levels in men with both secondary hypogonadism and erectile dysfunction: who does and does not benefit? Int. J. Impot. Res. (2003) 15(3):156-165.
84. SHABSIGH A, KANG Y, SHABSIGH R et al.: Clomiphene citrate effects on testosterone/estrogen ratio in male hypogonadism. J. Sex. Med. (2005) 2(5):716-721.
85. CHRISTENSEN RB, MATSUMOTO AM, BREMNER WJ: Idiopathic hypogonadotropic hypogonadism with anosmia (Kallmann's syndrome). Endocrinologist (1992) 2(5):332-340.
86. GOOREN L: Hypogonadotropic hypogonadal men respond less well to androgen substitution treatment than hypergonadotropic hypogonadal men. Arch. Sex. Behav. (1988) 17(3):265-270.
87. JOHNSEN SG: Maintenance of spermatogenesis induced by HMG treatment by means of continuous HCG treatment in hypogonadotrophic men. Acta Endocrinol. (Copenh.) (1978) 89(4):763-769.
88. VICARI E, MONGIOI A, CALOGERO AE et al.: Therapy with human chorionic gonadotrophin alone induces spermatogenesis in men with isolated hypogonadotrophic hypogonadism - long-term follow-up. Int. J. Androl. (1992) 15(4):320-329.
89. LIU PY, WISHART SM, HANDELSMAN DJ: A double-blind, placebo-controlled, randomized clinical trial of recombinant human chorionic gonadotropin on muscle strength and physical function and activity in older men with partial age-related androgen deficiency. J. Clin. Endocrinol. Metab. (2002) 87(7):3125-3135.
90. JENSTER G, VAN DER KORPUT HA, VAN VROONHOVEN C et al.: Domains of the human androgen receptor involved in steroid binding, transcriptional activation, and subcellular localization. Mol. Endocrinol. (1991) 5(10):1396-1404.
91. FRENCH FS, LUBAHN DB, BROWN TR et al.: Molecular basis of androgen insensitivity. Recent Prog. Horm. Res. (1990):461-438; discussion 38-42.
92. SIMENTAL JA, SAR M, LANE MV et al.: Transcriptional activation and nuclear targeting signals of the human androgen receptor. J. Biol. Chem. (1991) 266(1):510-518.
93. CHAMBERLAIN NL, DRIVER ED, MIESFELD RS: The length and location of CAG trinucleotide repeats in the androgen receptor N-terminal domain affect transactivation function. Nucleic Acids Res. (1994) 22(15):3181-3186.
94. MHATRE AN, TRIPIRO MA, KAUFMAN M et al.: Reduced transcriptional regulatory competence of the androgen receptor in X-linked spinal and bulbar muscular atrophy. Nat. Genet. (1993) 5(2):184-188.
95. CHOONG CS, KEMPPAINEN JA, ZHOU ZX, WILSON EM: Reduced androgen receptor gene expression with first exon CAG repeat expansion. Mol. Endocrinol. (1996) 10(12):1527-1535.
96. ZITZMANN M, BRUNE M, KORNMANN B et al.: The CAG repeat polymorphism in the androgen receptor gene affects bone density and bone metabolism in healthy males. Clin. Endocrinol. (Oxf.) (2001) 55(5):649-657.
97. ZITZMANN M, BRUNE M, KORNMANN B et al.: The CAG repeat polymorphism in the AR gene affects high density lipoprotein cholesterol and arterial vasoreactivity. J. Clin. Endocrinol. Metab. (2001) 86(10):4867-4873.
98. ZITZMANN M, GROMOLL J, VON ECKARDSTEIN A, NIESCHLAG E: The CAG repeat polymorphism in the androgen receptor gene modulates body fat mass and serum concentrations of leptin and insulin in men. Diabetologia (2003) 46(1):31-39.
99. ZITZMANN M, DEPENBUSCH M, GROMOLL J, NIESCHLAG E: X-chromosome inactivation patterns and androgen receptor functionality influence phenotype and social characteristics as well as pharmacogenetics of testosterone therapy in Klinefelter patients. J. Clin. Endocrinol. Metab. (2004) 89(12):6208-6217.
100. WALSH S, ZMUDA JM, CAULEY JA et al.: Androgen receptor CAG repeat polymorphism is associated with fat-free mass in men. J. Appl. Physiol. (2005) 98(1):132-137.
101. ZINN AR, RAMOS P, ELDER FF et al.: Androgen receptor CAGn repeat length influences phenotype of 47, XXY (Klinefelter) syndrome. J. Clin. Endocrinol. Metab. (2005) 90(9):5041-5046.
102. SNYDER PJ: Hypogonadism in elderly men - what to do until the evidence comes. N. Engl. J. Med. (2004) 350(5):440-442.
103. BHASIN S, SINGH AB, MAC RP et al.: Managing the risks of prostate disease during testosterone replacement therapy in older men: recommendations for a standardized monitoring plan. J. Androl. (2003) 24(3):299-311.